Back to Results

Alpha Tau Medical Ltd (DRTS)

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company listed on the NASDAQ under the ticker DRTS. The company is focused on developing and commercializing Alpha DaRT, a diffusing alpha-emitters radiation therapy intended for solid tumors. Its program is being evaluated in clinical studies across several cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers, alongside additional preclinical work in mouse and human-derived tumor models. Alpha Tau Medical is headquartered in Jerusalem, Israel.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-DRTS
$11.64
-23.1% Downside
Overvalued
$17.80
17.6% Upside
Fair
Fair
0.0%
November 24, 2026
32.5x
1.398 B
1.346 B
1.0%
69.4%
-0.3
17.4%
Valuation • Fair Value

Alpha Tau Medical Ltd (NASDAQ-DRTS) Fair Value by Valuation Model

Review the available estimates for Alpha Tau Medical Ltd (NASDAQ-DRTS), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$11.64

Estimated downside of 23.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$13.15

Discounted cash flow valuation reference.

Comps Fair Value

$9.37

Comparable-company valuation reference.

Analyst Price Target

$17.80

Analysts imply upside of 17.6%.

How to read these valuation models

Use the 5 available valuation references for Alpha Tau Medical Ltd (NASDAQ-DRTS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Alpha Tau Medical Ltd (NASDAQ-DRTS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

1.323 M

Forward revenue estimate.

EBITDA

-48.76 M

Current operating profitability reference.

EBITDA Forecast

-54.638 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Alpha Tau Medical Ltd (NASDAQ-DRTS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Alpha Tau Medical Ltd (NASDAQ-DRTS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-0.3

Lower score that deserves closer risk review.

FCF / Net Income

17.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Alpha Tau Medical Ltd (NASDAQ-DRTS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Alpha Tau Medical Ltd (NASDAQ-DRTS)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 24, 2026

Days to Earnings

63

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Alpha Tau Medical Ltd (NASDAQ-DRTS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Alpha Tau Medical Ltd (NASDAQ-DRTS) Stock Forecast & Technical Outlook

Review Alpha Tau Medical Ltd (NASDAQ-DRTS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Alpha Tau Medical Ltd (NASDAQ-DRTS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Alpha Tau Medical Ltd (NASDAQ-DRTS) has a Strong Buy consensus, with 3 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 1
Sell 0
FAQ • Fast Investor Answers

Alpha Tau Medical Ltd (NASDAQ-DRTS) Stock FAQ

Data-supported answers about Alpha Tau Medical Ltd (NASDAQ-DRTS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$11.64
Estimated downside 23.1%
Valuation Rating
Overvalued
Estimated downside of 23.1%
Analyst Target
$17.80
Implied upside 17.6%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Alpha Tau Medical Ltd (NASDAQ-DRTS) is $11.64. This implies an estimated downside of 23.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 23.1% versus the current market price.

The available analyst price target for Alpha Tau Medical Ltd (NASDAQ-DRTS) is $17.80. The analyst target implies estimated upside of 17.6%.

The current financial health read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Alpha Tau Medical Ltd (NASDAQ-DRTS) is November 24, 2026.

The latest available data indicates no current dividend yield for Alpha Tau Medical Ltd (NASDAQ-DRTS).

The current market capitalization listed for Alpha Tau Medical Ltd is 1.398 B.

The current enterprise value listed for Alpha Tau Medical Ltd is 1.346 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Alpha Tau Medical Ltd is NASDAQ-DRTS, and the stock is listed on NASDAQ.

Alpha Tau Medical Ltd (NASDAQ-DRTS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Alpha Tau Medical Ltd is 1.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Alpha Tau Medical Ltd is 69.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 142 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.1 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 65.099 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.173 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.847 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.185 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 41.084 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 33.785 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 31.756 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.674 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 29.933 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.452 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 20.357 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 17.926 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.107 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.581 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 12.242 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.566 B